MS
Siemens Healthineers, Novartis Ink Deal to Develop Assays With Initial Focus on MS Therapeutics
An initial program aims at the development of a serum neurofilament light chain immunoassay to support Novartis' MS and other neuroscience programs.
The agreement gives Quanterix an opportunity to explore the clinical utility of its Nf-l marker without having to move its instruments into the clinical space.
ResearchDx, Abreos Bio Partner on Test for MS, Crohn's Disease
The partners will make a test for monitoring Tysabri available to clinicians and clinical trial partners through ResearchDx's reference laboratory.
The firm aims to integrate protein biomarker measurements, data from patient wearables, and imaging to improve treatment and management of multiple sclerosis.
In studies of 140 multiple sclerosis patients and controls, the researchers identified two blood-based metabolites as potential markers of the disease.